Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.

Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ.

Br J Cancer. 2011 Jul 26;105(3):372-81. doi: 10.1038/bjc.2011.243. Epub 2011 Jul 5.

2.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

3.

Regulation of Chk1 by its C-terminal domain.

Kosoy A, O'Connell MJ.

Mol Biol Cell. 2008 Nov;19(11):4546-53. doi: 10.1091/mbc.E08-04-0444. Epub 2008 Aug 20.

4.

Turning off the G2 DNA damage checkpoint.

Calonge TM, O'Connell MJ.

DNA Repair (Amst). 2008 Feb 1;7(2):136-40. Epub 2007 Sep 11. Review.

5.

Deciphering cellular states of innate tumor drug responses.

Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S.

Genome Biol. 2006;7(3):R19. Epub 2006 Mar 15.

Supplemental Content

Write to the Help Desk